Levobupivacaina Molteni (Levobupivacaine)

Levobupivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. This prevents sodium influx, halting the generation and propagation of action potentials, which results in a reversible loss of sensation in the targeted area.

The dose of Levobupivacaina Molteni is determined by the prescribing clinician based on the specific procedure, patient characteristics, and desired depth of block. Dosing guidelines are provided in the product’s prescribing information and must be individualized.

The pregnancy category for levobupivacaine is listed as unknown. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant, and after careful evaluation by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of action with a lower risk of cardiotoxicity and central nervous system toxicity. Clinicians often prefer levobupivacaine for procedures where a safer cardiac profile is desirable, while maintaining effective analgesia.

Store the product below 25 °C in its original container, protecting it from moisture and direct light. Do not freeze. Before use, inspect the solution for particulate matter or discoloration and handle with aseptic technique appropriate for injectable sterile solutions.

Levobupivacaina Molteni is administered by a qualified healthcare professional via epidural, infiltration, or intrathecal injection. The route and technique are selected according to the clinical indication, and the drug is injected slowly while monitoring the patient’s vital signs and neurological status.

Serious risks include central nervous system toxicity such as seizures or loss of consciousness, and cardiovascular events like severe arrhythmias, cardiac arrest, or profound hypotension. Immediate recognition and supportive management are essential if these events occur.

Patients with a known hypersensitivity to levobupivacaine or other amide‑type local anesthetics should avoid this product. Caution is also advised in individuals with significant cardiac conduction disorders, severe hepatic impairment, or those receiving interacting medications that increase toxicity risk.